KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBT Margin (2016 - 2025)

Boston Scientific's EBT Margin history spans 17 years, with the latest figure at 13.25% for Q4 2025.

  • For Q4 2025, EBT Margin rose 42.0% year-over-year to 13.25%; the TTM value through Dec 2025 reached 16.86%, up 324.0%, while the annual FY2025 figure was 16.86%, 324.0% up from the prior year.
  • EBT Margin for Q4 2025 was 13.25% at Boston Scientific, down from 18.54% in the prior quarter.
  • Across five years, EBT Margin topped out at 18.59% in Q2 2025 and bottomed at 3.81% in Q4 2021.
  • The 5-year median for EBT Margin is 12.96% (2023), against an average of 12.54%.
  • The largest annual shift saw EBT Margin surged 2501bps in 2021 before it crashed -874bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 3.81% in 2021, then soared by 221bps to 12.21% in 2022, then rose by 11bps to 13.56% in 2023, then dropped by -5bps to 12.83% in 2024, then rose by 3bps to 13.25% in 2025.
  • Per Business Quant, the three most recent readings for BSX's EBT Margin are 13.25% (Q4 2025), 18.54% (Q3 2025), and 18.59% (Q2 2025).